Riskpilot← Back to searchSign inGet full accessVoisin Consulting Life Sciences ApS
APSActiveCVR 21857890Klosterstræde 23Engineering activities and related technical consultancy · NACE 7112Est. 19993 employees
Revenue 2024
DKK 4M
-37% vs 2023
EBITDA margin
-35.9%
+40% vs 2023
Equity ratio
-129.3%
Financial strength
Net profit 2024
DKK -1,5M
+26% vs 2023
| Revenue | DKK 4M | -37% |
| EBITDA | DKK -1,4M | +40% |
| Net profit | DKK -1,5M | +26% |
| Total assets | DKK 2,7M | -24% |
| Equity | DKK -3,5M | -72% |
| Employees | 3 | — |
Legal name
Voisin Consulting Life Sciences ApS
CVR number
21857890
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
28. juni 1999
Share capital
DKK 125.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med et medlem af bestyrelsen eller af bestyrelsens formand i forening med en direktør.
Company purpose
Selskabets formål er at udarbejde ansøgninger til brug for registering af lægemidler, dokumentationer og dermed beslægtet virksomhed
Address
Klosterstræde 23
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 18.174 | 19.952 | 12.490 | 6.338 | 3.997 |
| Staff expenses | -13.466 | -18.129 | -15.237 | -8.722 | -5.433 |
| EBITDA | 4.707 | 1.823 | -2.748 | -2.384 | -1.436 |
| Depreciation & amort. | -230 | -316 | -212 | -139 | -51 |
| EBIT | 4.478 | 1.507 | -2.959 | -2.523 | -1.487 |
| Net financials | -28 | -38 | -63 | -30 | -13 |
| Profit before tax | 4.450 | 1.469 | -3.023 | -2.553 | -1.500 |
| Tax | 980 | 325 | -661 | -561 | -25 |
| Net profit | 3.470 | 1.144 | -2.362 | -1.992 | -1.475 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7.697 | 7.602 | 6.404 | 3.602 | 2.737 |
| Equity | 3.148 | 2.292 | -70 | -2.063 | -3.538 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4.484 | 5.227 | 6.474 | 5.665 | 6.275 |
| Total debt | 4.484 | 5.227 | 6.474 | 5.665 | 6.275 |
EBITDA margin
-35.9%
This company
15.8%
Market median
-327% vs market
20202024
Equity ratio
-129.3%
This company
38.2%
Market median
-438% vs market
20202024
Return on equity
-147524400.0%
This company
18.4%
Market median
-801763143% vs market
20202024
Net profit margin
-36.9%
This company
8.1%
Market median
-556% vs market
20202024
Asset turnover
1.46×
This company
1.12×
Market median
+30% vs market
20202024
Debt / equity
1.77×
This company
0.62×
Market median
-185% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
IM Founder | Founder | 1999 |
JH Chief Executive Officer | Chief Executive Officer | 2026 |
| Former (5) | ||
CL Management | Management | 2011 – 2021 |
JD Management | Management | 1999 – 2013 |
LR Management | Management | 2011 – 2021 |
CC Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
HC Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2026 | |
| Chairman | 2019 | |
| Board of Directors | 2025 | |
| Board of Directors | 2019 | |
| Former (5) | ||
| Board of Directors | 2023 – 2026 | |
| Board of Directors | 2021 – 2024 | |
| Board of Directors | 2019 – 2021 | |
| Board of Directors | 2019 – 2021 | |
| Board of Directors | 2024 – 2026 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2019 | |
| Company | 50–66.65% | 50–66.65% | 2015 | |
| Company | 50–66.65% | 50–66.65% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Voisin Consulting Life Sciences ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Inge Merete Walløe Andersen | Founder | 0 companies |
| Connie Lyngbek Thestrup | Management | 0 companies |
| Jan Hellqvist | Chief Executive Officer | 0 companies |
| Jørn Dahl Andersen | Management | 0 companies |
| Lillan Rejkjær | Management | 0 companies |
| Cécile Crozatier | Chief Executive Officer | 0 companies |
| Henrik Carlheim Dørge | Chief Executive Officer | 0 companies |
| Décébal Romulus Bora | Board of Directors | 0 companies |
| Guillaume Pierre Henry Béjot | Board of Directors | 0 companies |
| Bertrand Laurent Gavoty | Board of Directors | 0 companies |
| Emmanuelle Marie Voisin-Lestringant | Chairman | 0 companies |
| Pauline France Lestringant | Board of Directors | 0 companies |
| Cécile Crozatier | Board of Directors | 0 companies |
| Pierre-Yves Jacques Paul Lestringant | Board of Directors | 0 companies |
| Jean-Luc Pascal Béjot | Board of Directors | 0 companies |
| Elodie SERRANO, épouse ARNAUD | Board of Directors | 0 companies |